Principal Investigator Daniela Rus
In response to new business models, accelerated timelines, and unforeseen market dynamics, healthcare companies are seeking to innovate rapidly and effectively to meet new challenges. A key criterion for success is the adoption of cutting-edge tools that derisk and accelerate the drug development process. Investment in these tools pays dividends across a company's pipeline.
Contact
Principal Investigator John Gabrieli
Principal Investigator Sangeeta Bhatia
Principal Investigator Patrick Jaillet